Loading...
NPI 1962804088 · Bristol, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Skippack Medical Lab, LLC is a clinical medical laboratory provider located in Bristol, Pennsylvania. This profile covers 20 Medicare and 24 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Skippack Medical Lab, LLC |
| Address | 200 Rittenhouse Circle East |
| City | Bristol |
| State | PA |
| ZIP | 19007 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 19, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $10.6M |
| Medicaid | $760.3K |
This provider’s revenue is heavily skewed toward Medicare: total Medicare revenue is $10.6M compared with total Medicaid revenue of $760.3K, making Medicare the dominant payer by scale. The NPI was enumerated 2014-09-19 (~12 years ago), so the organization has an established enrollment history despite the recent COVID-focused billing profile.
Medicare billing is extremely concentrated: the precomputed top-3 Medicare codes account for 99.0% of Medicare revenue, and K1034 alone represents $10.6M (97.9% of the provider’s Medicare revenue). K1034 (provision of nonprescription self‑administered COVID-19 tests) is reported as an extreme outlier nationally (ranks #49 of 30143 providers nationally; 100th percentile), indicating this provider’s Medicare business is functionally centered on large-volume COVID self-test provisioning.
Medicaid revenue is likewise concentrated in COVID testing codes: the precomputed top-3 Medicaid codes account for 95.2% of Medicaid revenue, led by U0004 at $564.1K (73.6%), G2023 at $112.7K (14.7%), and U0005 at $53.2K (6.9%). Those codes correspond to high‑throughput SARS‑CoV‑2 testing and specimen collection, showing the provider’s Medicaid-facing services mirror its Medicare focus on COVID diagnostics rather than broad ambulatory lab panels.
Competitive standing differs by payer and code: for Medicare the provider is a national outlier on K1034 (rank #49 of 30143; 100th percentile), reflecting extraordinarily high volume versus peers for that specific self‑test code. By contrast, other Medicare codes such as 87798 (rank #293 of 1319; 78th percentile) and 87481 (rank #337 of 1117; 70th percentile) show only typical, unremarkable volumes, suggesting the provider’s national prominence is concentrated in one product line.
Within Pennsylvania Medicaid, the provider is a meaningful in‑state participant for COVID testing: U0004 ranks #12 of 73 providers in-state (85th percentile) and G2023 ranks #7 of 101 providers in-state (94th percentile), indicating above-average state activity on high-throughput testing and specimen collection. However, for many ancillary Medicaid lab codes the provider ranks in mid- to lower-percentiles, so its competitive footprint in non‑COVID testing remains modest.
The code mix implies an operational model built around mass COVID testing logistics: heavy use of K1034 (self‑collected, nonprescription tests), U0004 and U0005 (high‑throughput molecular assays), plus G2023 (specimen collection) points to scale in kit provisioning, centralized lab processing, and specimen intake rather than traditional clinic-based phlebotomy or diversified diagnostic lines. Routine clinical laboratory codes (examples include 84443 TSH, 80061 lipid panel, 80053 CMP) appear on the Medicare file but contribute only small, single‑digit‑thousand dollar amounts, reinforcing that general clinical testing is secondary to the COVID testing business.
This extreme revenue concentration creates both opportunity and exposure: reliance on a very small set of COVID-related codes (Medicare top‑3 = 99.0% of Medicare revenue; Medicaid top‑3 = 95.2% of Medicaid revenue) means reimbursement policy changes or demand shifts for those specific services would materially impact financial performance. For payers and network planners, the provider represents a specialized, high-volume supplier for SARS‑CoV‑2 testing and self‑test provisioning rather than a full‑spectrum clinical laboratory partner.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 886,040 | $10 | $10.6M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3,140 | $30 | $106.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 480 | $30 | $16.3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 170 | $70 | $12.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 530 | $20 | $8.4K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 250 | $30 | $8.4K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 250 | $30 | $8.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 240 | $30 | $8.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 240 | $30 | $8.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 240 | $30 | $8.2K |
Showing 1–10 of 20
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
20 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 11 | 40 | 1,250 | $30 | $1.1M |
| 87481 | 11 | 20 | 940 | $30 | $574.2K |
| 87653 | 10 | 20 | 360 | $30 | $175.8K |
| U0004 | 7 | 10 | 190 | $70 | $105.8K |
| 87640 | 11 | 30 | 140 | $30 | $60.4K |
| G2023 | 6 | 10 | 160 | $20 | $36.4K |
| 87591 | 6 | 20 | 210 | $30 | $34.2K |
| 87486 | 4 | 10 | 220 | $30 | $33.9K |
| U0005 | 15 | 30 | 290 | $20 | $24.7K |
| 80053 | 51 | 220 | 110 | $10 | $21.6K |
Showing 1–10 of 20
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 8,680 | $70 | $564.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 8,670 | $10 | $112.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,530 | $20 | $53.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 280 | $50 | $13.5K |
| 86328 | The lab analyst performs a single–step immunoassay to qualitatively or semiquantitatively evaluate the patient’s specimen for antibodies to the severe acute respiratory syndrome coronavirus 2… | 230 | $50 | $10.7K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,820 | $1 | $2.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 190 | $10 | $2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 190 | $10 | $1.9K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 190 | $10 | $1.3K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 190 | $10 | $1.1K |
Showing 1–10 of 24
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
24 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 152 | 210 | 730 | $40 | $689.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 12 | 70 | 620 | $60 | $464.8K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 28 | 60 | 110 | $220 | $151.2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 16 | 30 | 220 | $30 | $139.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 39 | 70 | 270 | $50 | $108.2K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 15 | 20 | 340 | $20 | $105.2K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 208 | 220 | 420 | $20 | $91.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 320 | 340 | 2,320 | $10 | $88.6K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 206 | 220 | 430 | $20 | $84.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 42 | 140 | 770 | $10 | $80.7K |
Showing 1–10 of 24
Other providers in the same ZIP code as Skippack Medical Lab, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Medarbor LLC | PA | Clinical Medical Laboratory | $12.3M | $15.8M |
| Prime Healthcare Services Lower Bucks LLC | PA | General Acute Care Hospital | $0 | $8.7M |
| Mark Burton | PA | Primary Podiatric Medicine Podiatrist | $302.9K | $0 |
| Atul Trivedi | PA | Cardiovascular Disease Physician | $161.9K | $0 |
| Lester Libfraind | PA | Diagnostic Radiology Physician | $136.1K | $0 |
| Ramesh Adiraju | PA | Vascular Surgery Physician | $119.2K | $1.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.